Orbimed Advisors Llc - Dec 27, 2023 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC. (ALPN)

Role
Director
Signature
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Stock symbol
ALPN
Transactions as of
Dec 27, 2023
Transactions value $
-$28,671,734
Form type
4
Date filed
12/29/2023, 04:18 PM
Previous filing
Dec 20, 2023
Next filing
Jan 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALPN Common Stock Sale -$3.25M -163K -4.45% $19.96 3.49M Dec 27, 2023 See footnotes F1, F3
transaction ALPN Common Stock Sale -$378K -18.9K -4.45% $19.96 407K Dec 27, 2023 See footnotes F2, F3
transaction ALPN Common Stock Sale -$533K -26.9K -0.77% $19.82 3.47M Dec 28, 2023 See footnotes F1, F3
transaction ALPN Common Stock Sale -$62K -3.13K -0.77% $19.82 403K Dec 28, 2023 See footnotes F2, F3
transaction ALPN Common Stock Sale -$21.9M -1.2M -34.49% $18.32 2.27M Dec 28, 2023 See footnotes F1, F3
transaction ALPN Common Stock Sale -$2.55M -139K -34.49% $18.32 264K Dec 28, 2023 See footnotes F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
F2 These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
F3 This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.